Physician profile
Alejandro Cintas
NPI 1427084888
$17,131.56
in general payments reported to CMS, 2019-2025
50 companies · $1,729 in 2025
The $1,729 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,177 · 2020: $2,359 · 2021: $3,087 · 2022: $2,865 · 2023: $2,227 · 2024: $1,688 · 2025: $1,729.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,571 · Education: $72.33.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,571.06 |
| Education | $72.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $3,192.32 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $2,030.89 | 2019-2025 | Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,452.61 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Amgen INC. | $1,411.59 | 2019-2025 | Repatha, Otezla, Otezla |
| Sanofi-Aventis U.S. LLC | $1,190.19 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $1,141.42 | 2021-2025 | |
| Lilly USA, LLC | $735.33 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $686.24 | 2019-2025 | Trelegy Ellipta |
| Janssen Pharmaceuticals, INC | $647.79 | 2019-2024 | Xarelto |
| Amarin Pharma, INC. | $632.65 | 2019-2022 | |
| Abbvie INC. | $486.03 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Novartis Pharmaceuticals Corporation | $469.45 | 2019-2023 | |
| Pfizer INC. | $421.06 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $366.30 | 2019-2025 | Xifaxan |
| Astellas Pharma US INC | $281.40 | 2019-2025 | Veozah |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alejandro Cintas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.